Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

the SB-509-401 study was safety, we also observed statistically significant and clinically relevant improvements in a number of quantitative measures of neurological health," said Edward Lanphier, Sangamo's president and CEO. "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and possibly restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We are encouraged by the data so far and are swiftly moving forward to the next stage of clinical development with our ongoing Phase 2 clinical trials. We expect to have data from our double blind Phase 2 clinical trial (SB-509-601) available in the fourth quarter of this year."

About SB-509

SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About the SB-509 Clinical Program

Sangamo has three ongoing Phase 2 studies in diabetics with sensory/motor neuropathy:

Phase 2 study of SB-509 for mild to moderate DN (SB-509-601)

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial is being conducted at multiple sites and is fully enrolled; data is expected to be available in the fourth quarter of 2008.

Approximately 100 subjects have been enrolled into the
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital ... to announce the opening of its new outpatient ... outpatient services to people with chronic, hard to ... which can lead to amputation, lower leg wounds ... have delayed closure, and traumatic injury wounds which ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... , , , ... SAN DIEGO, Sept. 18, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM ... for Overweight and Obesity Management) trial and completes the lorcaserin Phase 3 ...
... , NEWNAN, Ga., Sept. 16 CeloNova ... make two presentations at the Cardiovascular and Interventional Radiology Society ... excellent clinical results in treating liver cancer. Professor Orsi and ... Italy have developed a technique to cut off the blood ...
Cached Medicine Technology:Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 2Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 3Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 4Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 5Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 6Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 7Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 8Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 9Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 10Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 11Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 12New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
(Date:7/14/2014)... NC (PRWEB) July 14, 2014 The ... the University of Pennsylvania to fund a clinical trial ... here to read Surviving Mesothelioma’s newly-posted article on ... plan to use the grant to enroll 102 ... years. Patients will receive a photosensitizing drug prior to ...
(Date:7/14/2014)... SC (PRWEB) July 14, 2014 Many diet ... a study by the School of Public Health at ... vegetable consumption had a near-zero effect on weight loss. Now ... be combine with some form of portion control ... method of monitoring portions and controlling how much is consumed, ...
(Date:7/14/2014)... Washington DC (PRWEB) July 14, 2014 ... MessageSolution, an industry leader and Microsoft gold partner will ... network with Microsoft partners from the world and to ... all Microsoft platforms of Exchange email server, Office 365, ... DC from July 13 to 17, 2014. , “In ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine ... with a Fall issue that hits newsstands nationwide on ... the healthy, natural and good for you life with ... beauty, travel, home, and entertaining all through Danny’s unique ... “Instead of gimmicky weight loss tips and fluffy celebrity ...
(Date:7/14/2014)... San Diego, CA (PRWEB) July 14, 2014 ... website daily regarding all the latest information from the ... Injection . , The FDA informed on July 11, ... Injection, USP, 1000 mL, Flexible Container, by Hospira Inc., ... is used for parenteral replacement of extracellular losses of ...
Breaking Medicine News(10 mins):Health News:New Research Could Expand Availability of Light-Based Mesothelioma Therapy, According to Surviving Mesothelioma 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3
... clinical trials, design may also mask risk of HIV drug ... new study questions whether vaginal microbicides being developed to help ... resistance from the virus that causes AIDS. , The ... Proceedings of the National Academy of Sciences , also shows ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
... WASHINGTON, July 10 Two leading U.S. House,Judiciary Committee ... Judiciary Committee and Rep. Lamar Smith, ranking member of ... B. Mukasey to,have the Department of Justice focus its ... seeking to gain control of,U.S. copper miner ASARCO., ...
... 2008 -- Later this month, thousands of scientists and health ... the 50th meeting of the American Association of Physicists in ... July 31, they will present the latest technologies for imaging ... facing the field today. , Whether X-rays for CT ...
... of a noisy Chicago restaurant during the breakfast rush ... many voices was the crucial test of new hearing ... University School of Medicine in St. Louis. The study showed ... the most challenging test for a hearing aid. ,But ...
... Va., July 10 Axiom Resource,Management, Inc., has been ... the field of healthcare information and technology. Healthcare,Informatics magazine ... June, 2008, ranking Axiom at number 76. Axiom moved ... at number 81 on the list., Axiom managing ...
Cached Medicine News:Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 2Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 3Health News:Waves, particles and medicine in Houston 2Health News:New hearing aid technology passes the restaurant noise test 2Health News:New hearing aid technology passes the restaurant noise test 3
Liquichek Cardiac Markers Control is a multi-analyte liquid control for monitoring cardiac assessment tests. Assayed values are available for major instruments....
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
Medicine Products: